Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment

Süren, Elçin; Özkaya, Dilek Bıyık; Çetinkaya, Ersan; Kalaycı, Mustafa; Yiğit, Kenan; Küçük, Mehmet Fatih; Erol, Muhammet Kazım

doi:10.1007/s10792-021-02188-z

Cited by 15 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 studies comparing bevacizumab with laser therapy, 6,24,[35][36][37][38][39][40][41][42][43] 6 studies comparing ranibizumab with laser, 10,44-48 5 studies comparing bevacizumab with ranibizumab, [53][54][55][56][57] 3 studies comparing bevacizumab, ranibizumab and laser, [50][51][52] 2 studies comparing aflibercept with laser, 12,49 1 study comparing ranibizumab and aflibercept, 58 1 study compared bevacizumab and aflibercept and 1 study compared bevacizumab, ranibizumab, aflibercept. 60 In total, these comprise 4686 eyes of 2408 infants that received primary treatment for ROP with bevacizumab (2081 eyes), ranibizumab (727 eyes), aflibercept (326 eyes), or laser (1552 eyes).…”

Section: Resultsmentioning

confidence: 99%

A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity

et al. 2022

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity

et al. 2022

View full text Add to dashboard Cite

“…96 On the other hand, the agents that perform a pan-blockade of VEGF-A, namely bevacizumab, ranibizumab and aflibercept, are more frequently described in studies concerning the therapy of retinopathy of prematurity. 97 Bevacizumab is a recombinant humanized monoclonal antibody, being the most widely used anti-VEGF agent for the treatment of ROP. However, recent studies have focused on ranibizumab and aflibercept as they appear to be safer and more effective therapeutic alternatives.…”

Section: Current Therapies Of Ropmentioning

confidence: 99%

Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies

Bezman¹,

Tiutiuca²,

Totolici³

et al. 2023

IJGM

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is a vasoproliferative disorder with an imminent risk of blindness, in cases where early diagnosis and treatment are not performed. The doctors' constant motivation to give these fragile beings a chance at life with optimal visual acuity has never stopped, since Terry first described this condition. Thus, throughout time, several specific advancements have been made in the management of ROP. Apart from the most known risk factors, this narrative review brings to light the latest research about new potential risk factors, such as: proteinuria, insulin-like growth factor 1 (IGF-1) and blood transfusions. Digital imaging has revolutionized the management of retinal pathologies, and it is more and more used in identifying and staging ROP, particularly in the disadvantaged regions by the means of telescreening. Moreover, optical coherence tomography (OCT) and automated diagnostic tools based on deep learning offer new perspectives on the ROP diagnosis. The new therapeutical trend based on the use of anti-VEGF agents is increasingly used in the treatment of ROP patients, and recent research sustains the theory according to which these agents do not interfere with the neurodevelopment of premature babies.

show abstract

“…Regarding the efficacy of the currently available anti-VEGF drugs, ranibizumab and bevacizumab have comparable effects in patients with wAMD, DME, or ROP. [45][46][47][48][49][50] In 11 clinical trials including 8341 wAMD patients, no difference in either the efficacy or severe side effects was found between aflibercept and ranibizumab. 51 By contrast, in patients with wAMD refractory to ranibizumab treatment, aflibercept showed better outcomes.…”

Section: Efficacies Of the Currently Available Anti-vegf Drugsmentioning

confidence: 99%

Antiangiogenic therapy for ocular diseases: Current status and challenges

Chen

Zhu

et al. 2023

MedComm – Future Medicine

View full text Add to dashboard Cite

Angiogenesis is the process of new blood vessel growth from pre-existing ones involving vascular endothelial cell activation, proliferation, migration, and tube formation. The vascular endothelial growth factor A (VEGF-A) is known to be a key factor that promotes angiogenesis. Pathological angiogenesis is a key and common feature of numerous ocular neovascular diseases, such as wet age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, and corneal neovascularization. Although anti-VEGF treatment has been a great success for the treatment of such ocular neovascular diseases, many challenges exist, such as limited efficacy, unresponsiveness in many patients, drug resistance, treatment burden due to repeated intravitreous injection, all of which incent much effort and enthusiasm to find new and better treatment for ocular neovascular diseases.In recent years, new antiangiogenic drug, targets and drug delivery methods have been developed. This perspective discusses the status of currently available therapies, challenges, opportunities, and potential new directions toward better therapies for ocular neovascular diseases.

show abstract

Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment

Cited by 15 publications

References 38 publications

A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity

A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity

Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies

Antiangiogenic therapy for ocular diseases: Current status and challenges

Contact Info

Product

Resources

About